There are 2137 resources available
794P - UK practices for treatment of relapse in seminoma testicular cancer
Presenter: Johnathan Joffe
Session: E-Poster Display
Resources:
Abstract
795TiP - Phase III study of the programmed cell death protein 1 inhibitor PF-06801591 plus bacillus Calmette-Guérin for non-muscle invasive bladder cancer
Presenter: Gary Steinberg
Session: E-Poster Display
Resources:
Abstract
796TiP - TROPHY-U-01 Cohort 3: Sacituzumab govitecan (SG) and pembrolizumab (pembro) in patients (pts) with progression or recurrence of metastatic urothelial cancer (mUC) after platinum (PLT)-based therapy
Presenter: Petros Grivas
Session: E-Poster Display
Resources:
Abstract
797TiP - RACE IT: A prospective, single arm, multicenter, phase II-trial to assess safety and efficacy of preoperative radiation therapy before radical cystectomy combined with immunotherapy in locally advanced urothelial carcinoma of the bladder (AB 65/18)
Presenter: Sebastian Schmid
Session: E-Poster Display
Resources:
Abstract
798TiP - Study EV-302: A 3-arm, open-label, randomized phase III study of enfortumab vedotin plus pembrolizumab and/or chemotherapy, versus chemotherapy alone, in untreated locally advanced or metastatic urothelial cancer
Presenter: Michiel van der Heijden
Session: E-Poster Display
Resources:
Abstract
799TiP - PROOF 302: A randomized, double-blind, placebo-controlled, phase III trial of infigratinib as adjuvant therapy in patients with invasive urothelial carcinoma harboring susceptible FGFR3 alterations
Presenter: Diederik Somford
Session: E-Poster Display
Resources:
Abstract
800TiP - Meet-URO 12: A randomized phase II trial of niraparib versus best supportive care (BSC) as maintenance treatment in patients with locally advanced or metastatic urothelial cancer (UC) whose disease did not progress after completion of first-line platinum-based chemotherapy
Presenter: Francesca Vignani
Session: E-Poster Display
Resources:
Abstract
801TiP - A phase II study of cabozantinib in combination with atezolizumab as neoadjuvant treatment for muscle-invasive bladder cancer (ABATE)
Presenter: Matthew Milowsky
Session: E-Poster Display
Resources:
Abstract
802TiP - Immune tumor microenvironment (TME) in correlation with peripheral blood immune biomarkers as prognostic factor in metastatic renal cell carcinoma (mRCC) patients treated with nivolumab: The multicentric retrospective Meet-URO 18 study
Presenter: Matteo Brunelli
Session: E-Poster Display
Resources:
Abstract
803TiP - Pilot study of cabozantinib efficacy, safety and tolerability in metastatic renal carcinoma in aged fragile patients
Presenter: Miguel Angel Climent Duran
Session: E-Poster Display
Resources:
Abstract